New antibody therapy shows promise Pediatric brain
Effective and safe treatments are needed for medulloblastoma, the most common type of cancerous brain tumor in children, especially whose cancer has spread to the spinal cord. A recent phase I clinical trial led by researchers has generated promising results for a new blocking antibody therapy that targets a protein critical to medulloblastoma cells' ability to multiply and spread. The findings are published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The antibody, called TB-403, recognizes placental growth factor (PlGF), over-expressed in some types of malignant tumors. The MGH research team previously showed that placental growth factor and its receptor neuropilin 1 (NRP1) are often overexpressed in human medulloblastomas and are required for its growth and progression in experimental models in mice.
That work also demonstrated that blocking the PlGF/NRP1 pathway in medulloblastoma models caused tumor regression, decreased spread to the spinal cord, and prolonged survival.
The investigators' phase I, open-label, multicenter dose-escalation study enrolled 15 children with relapsed or refractory medulloblastoma that did not respond to standard treatments. Patients received increasing doses of the anti-human placental growth factor antibody TB-403 (20 mg/kg, 50 mg/kg, 100 mg/kg, and 175 mg/kg), and all patients received two doses of TB-403 in the first cycle of treatment.
The maximum tolerated dose defined in clinical trials as the highest dose of a drug that does not cause unacceptable toxicity-was not reached. Moreover, although there were no partial tumor responses (significant reductions in tumor size) in this treatment refractory population, seven of 11 patients experienced disease stabilization-stoppage of progression-and which persisted for more than 100 days in four of those patients.
The investigators concluded that TB403 treatment was well tolerated and induced stable disease in some medulloblastomas in a setting with no effective treatments available.
These findings indicate that treatment with TB-403 should be tested in larger studies of children with advanced medulloblastoma and perhaps at earlier stages, in combination with standard therapies, concluded the researchers.
Reference: "New antibody therapy shows promising phase I clinical trial results for advanced, treatment-refractory pediatric brain cancer; MASSACHUSETTS GENERAL HOSPITAL,Clinical Cancer Research.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.